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We appreciate the interest by Jarai and colleagues in our
recent paper (1). Unfortunately, from the FRISC-II data we
cannot answer the questions raised. Further subgrouping of
the data makes the groups small and estimates unreliable.
A number of problems arise when trying to define
optimal decision limits in patients with non–ST-segment
elevation acute coronary syndrome. One problem is that the
level of N-terminal pro-brain natriuretic peptide (NT-
proBNP) changes over time after presentation. Previous
studies have shown that the level of NT-proBNP increases
during the first 14 to 48 h after a myocardial infarction (2),
and thereby gradually decreases at least for six months (3).
Therefore, the timing in relation to the acute event will be
important when defining optimal decision limits for NT-
proBNP in patients with non–ST-segment elevation acute
coronary syndromes. Thus, NT-proBNP levels measured
after a median time of 9 h from the last episode of
symptoms in the GUSTO-IV trial (4) does not correspond
to levels measured after a median time of 39 h in the
FRISC-II trial (1).
Another important issue is whether decision limits should
be related to gender. It is well known that NT-proBNP
levels are higher in women (5). The reason for this gender-
related difference is still unclear. The fact that the age-
related mortality is lower in women than in men suggests
that the reason for this gender difference does not cause
increased mortality. Therefore, we believe gender differ-
ences should be considered when determining suitable
decision limits. Evidently, further studies regarding the best
time point for analysis and the most appropriate decision
limit are needed.
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Troponin and Outcomes
We read with interest the report of Kontos et al. (1), which
showed that any detectable troponin I in the serum of
patients admitted with chest pain was associated with worse
outcomes. We recently reported the results of a similar study
involving troponin T levels (2), and we found that among
428 patients admitted with ongoing chest pain, troponin T
levels that were detectable but within the range reported as
normal were markers of an increased risk of death/
subsequent myocardial infarction/revascularization during
the four-month follow-up.
We would like to comment on two aspects of the Kontos
et al. (1) study: 1) the conclusion that most of the tests with
detectable cardiac troponin I in the normal range “represent
analytical false positive results due to the assays themselves”
and 2) what to call detectable troponin values within the
normal range. Troponin assays are exquisitely sensitive and,
conceptually, a minor event, that cannot be detected clini-
cally, can lead to a detectable level of troponin in the serum.
Instead of thinking of detectable levels of troponin in
patients with a negative subsequent workup as “false posi-
tive,” we believe that the patients should be thought of as
having suffered a minor event, be it transient vascular
occlusion, blood pressure changes, short runs of ventricular
arrhythmias, or any number of other conditions (3).
Whereas most patients suffer no testable harm from such
events, some do, and hence the observed higher risk of poor
outcomes.
Finally, in our report we referred to detectable troponin
within the normal range as “marginal” troponin, indicative
of “minor myocardial injury.” We believe these terms aid in
thinking about these patients, and we would advocate their
continued use.
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